Table 2

Baseline and follow-up values of echocardiographic characteristics of the study group

	Spironolactone (n=58)			Placebo (n=55)			p Value
Characteristic	Baseline	Follow-up	p Value	Baseline	Follow-up	p Value	ΔSpironolactone vs ΔPlacebo
LV end-diastolic dimension, mm	52.3±5.5	52.2±5.2	0.78	51.4±4.5	51.6±3.8	0.57	0.57
IVS, mm	11.9±1.1	11.3±1.1	0.001	11.9±1.3	11.7±1.4	0.28	0.16
PW, mm	9.9±1.1	9.5±1.0	0.05	9.7±1.4	9.7±1.5	0.86	0.08
LV mass index, g/m^2.7	57.8±10.5	54.3±10.1	0.003	56.5±10.3	56.3±11.3	0.79	0.02
Left atrial dimension, mm	43.5±4.7	42.3±4.1	0.01	42.8±4.4	42.7±4.4	0.81	0.04
E/e′	12.3±3.0	11.2±3.0	0.007	11.4±2.6	11.3±2.9	0.55	0.05
E/A	0.98±0.25	0.99±0.23	0.64	0.97±0.17	0.99±0.21	0.26	0.61
DT, ms	229±44	231±40	0.79	238±41	236±40	0.74	0.66
Sm, cm/s	5.8±1.2	6.2±1.3	0.006	6.0±1.2	5.9±1.1	0.37	0.001
Em, cm/s	5.7±1.4	6.6±1.4	0.0001	6.0±1.4	5.9±1.3	0.46	0.0001
Strain, %	17.4±2.3	19.9±2.2	0.0001	17.6±2.1	17.5±2.0	0.44	0.0001
SR, 1/s	1.42±0.21	1.60±0.20	0.0001	1.43±0.20	1.43±0.18	0.87	0.0001
IB AS, dB	−14.3±5.8	−16.9±5.1	0.004	−15.9±5.3	−16.1±5.1	0.82	0.02
IB post, dB	−25.0±5.5	−27.6±5.5	0.004	−24.9±6.2	−25.1±5.5	0.71	0.03

Values are mean±SD. ΔPlacebo indicates change in the placebo group during follow-up, and ΔSpironolactone the change in the spironolactone group during follow-up.
DT, diastolic flow wave; E/A, the ratio of peak early to late diastolic flow velocities; E/e′, ratio of mitral inflow early diastolic velocity to peak early diastolic mitral annular velocity; Em, myocardial peak early diastolic velocity; IB AS, calibrated integrated backscatter in the basal anteroseptum; IB post, calibrated integrated backscatter in the basal posterior wall; IVS, interventricular septal thickness; LV, left ventricular; PW, LV posterior wall thickness; Sm, peak systolic velocity; SR, peak systolic strain rate.